4-hydroxy-4-(4-methylphenyl)-1-methylpiperidine | 36887-12-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-hydroxy-4-(4-methylphenyl)-1-methylpiperidine
• 英文别名: 1-methyl-4-(4-methylphenyl)-4-piperidinol；1-methyl-4-p-tolyl-piperidin-4-ol；1-Methyl-4-(4-methylphenyl)piperidin-4-OL
• CAS: 36887-12-4
• 化学式: C₁₃H₁₉NO
• 分子量: 205.3
• InChiKey: VQXHLLCGGDWBSL-UHFFFAOYSA-N

物化性质

• 沸点：
  339.9±42.0 °C(Predicted)
• 密度：
  1.061±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-hydroxy-4-(4-methylphenyl)-1-methylpiperidine 在 sodium chloride 作用下， 以 N-甲基乙酰胺 、 六氟苯 、 乙醚 、 乙醇 为溶剂， 以3.2 g (65%)的产率得到4-(4-methylphenyl)-1-methyl-4-(2,3,4,5,6-pentafluorophenoxy) piperidine hydrochloride
  参考文献：
  名称：

  4-Pentafluorophenoxypiperidines

  摘要：

  4-五氟苯氧哌啶和利用其化合物或组合物缓解疼痛、治疗抑郁症、癫痫和高血压的方法被披露。

  公开号：

  US04914204A1
• 作为产物：
  描述：

  N-甲基-4-哌啶酮 、 对甲苯基溴化镁 以 乙醚 为溶剂， 反应 1.0h， 生成 4-hydroxy-4-(4-methylphenyl)-1-methylpiperidine
  参考文献：
  名称：

  In vivo intracerebral microdialysis studies in rats of MPP+ (1-methyl-4-phenylpyridinium) analogs and related charged species

  摘要：

  The in vivo dopaminergic neurotoxic properties of 45 MPTP and MPP+ analogues and related compounds were examined by an intrastriatal microdialysis assay in conscious rats. MPP(+)-like toxicity, as evidenced by the irreversible effects on DA release and enhancement of lactate formation, was observed with a variety of structural types although no compound was more toxic than MPP+. The following global structure-toxicity relationships could be derived: (1) only permanently charged compounds showed neurotoxic effects; (2) with the exception of amino groups, hydrophilic substituents abolished toxicity; (3) activity was enhanced by lipophilic groups although increased steric bulk around the nitrogen atom tended to decrease activity; (4) nonaromatic, quaternary systems (methiodide of MPTP, guanidinium derivatives) were only weakly toxic; and (5) certain bi- and tricyclic systems, including putative metabolites of potential endogenous MPTP-like compounds, were weakly toxic. The lack of toxic effects following perfusions with DA itself confirmed that MPTP dopaminergic neurotoxicity is not likely to be mediated by the MPP(+)-induced release of DA. With some interesting exceptions, these in vivo data correlate reasonably well with in vitro data on the nerve terminal uptake properties and the inhibitory effects on mitochondrial respiration of these compounds.

  DOI：

  10.1021/jm00170a029

文献信息

• 4-Aryl-4-aryloxypiperidines
  申请人：John Wyeth and Brother Limited

  公开号：US04325953A1

  公开（公告）日：1982-04-20

  4-Aryl-4-aryloxypiperidines of the general formula (I) ##STR1## and their pharmaceutically acceptable acid addition salts, wherein R.sup.1 and R.sup.2 are hydrogen or lower alkyl, R.sup.3 is hydrogen, lower alkyl or benzyl, Ar is phenyl optionally substituted by one or more halogen, trifluoromethyl, lower alkyl, lower alkoxy, nitro or amino groups and Ar.sup.1 is a phenyl radical optionally substituted by one or more cyano, methylsulphinyl, methylsulphonyl, lower alkoxy, trifluoromethyl, lower alkyl, lower alkenyl, halogen, nitro, amino or acylamino groups or an aromatic heterocyclic mono- or di-cyclic radical, exhibit activity on the central nervous system, e.g. as antidepressants.

  通用式(I)的4-芳基-4-芳氧基哌啶及其药学上可接受的酸盐，其中R.sup.1和R.sup.2是氢或较低的烷基，R.sup.3是氢、较低的烷基或苄基，Ar是苯基，可选择地被一个或多个卤素、三氟甲基、较低的烷基、较低的烷氧基、硝基或氨基取代，Ar.sup.1是一个苯基基团，可选择地被一个或多个氰基、甲磺基、磺酰基甲基、较低的烷氧基、三氟甲基、较低的烷基、较低的烯基、卤素、硝基、氨基或酰胺基团或芳香族杂环单环或双环基团取代，表现出对中枢神经系统的活性，例如作为抗抑郁药。
• [EN] TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉ DE TRIAZOLOPYRIDINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015032286A1

  公开（公告）日：2015-03-12

  Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.

  本文描述了化合物的公式0、公式I和公式II，以及作为Janus激酶抑制剂使用的方法。
• 4-pentafluorophenoxypiperidines
  申请人：Hoechst-Roussell Pharmaceuticals Inc.

  公开号：US04954511A1

  公开（公告）日：1990-09-04

  4-Phenafluorophenoxypiperidines and methods for alleviating pain and treating depression, convulsions, and hypertension utilizing compounds or compositions thereof are disclosed.

  本文揭示了4-Phenafluorophenoxypiperidines及其化合物或组合物的使用方法，用于缓解疼痛和治疗抑郁症、惊厥和高血压。
• Substituted Pyrazole Compounds
  申请人：Ladouceur Gaetan

  公开号：US20110318393A1

  公开（公告）日：2011-12-29

  Provided are substituted pyrazole compounds which are useful as protein kinase inhibitors, compositions comprising the compounds, and methods of use thereof. The protein kinase inhibitors are particularly for inhibition of Aurora A (Aurora-2) protein kinase and are useful in the treatment of diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.

  提供了替代吡唑化合物，可用作蛋白激酶抑制剂，包括这些化合物的组合物以及使用方法。这些蛋白激酶抑制剂特别用于抑制极化A（Aurora-2）蛋白激酶，并且可用于治疗与蛋白激酶相关的疾病，尤其是与Aurora-2相关的疾病，如癌症。
• TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Genentech, Inc.

  公开号：US20160185780A1

  公开（公告）日：2016-06-30

  Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.

  本文描述了化学式为0、化学式I和化学式II的化合物以及作为Janus激酶抑制剂的使用方法。